S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer
To compare the progression free survival(PFS) and safety of TS-S vs. TX-X in Patients With Advanced Breast Cancer first-line treatment
Breast Cancer Recurrent
DRUG: S1 plus Docetaxel|DRUG: Capecitabine plus Docetaxel
progression free survival, 2 years
overall survival, 1 year|objective response rate, 2 years|Disease control rate, 2 years
To compare progression free survival (PFS) of the S-1 combined with docetaxel followed by maintenance treatment with S-1 and capecitabine combined with docetaxel followed by maintenance therapy with capecitabine in patients with advanced breast cancer first-line treatment.